Načítá se...
Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
Activating KRAS mutations are present in 25% of human cancer. Although oncogenic Ras was deemed “undruggable” in the past, recent efforts led to the development of pharmacological inhibitors targeting the KRAS(G12C) mutant, which have shown promise in early clinical trials. The development of allele...
Uloženo v:
| Vydáno v: | Innovation (Camb) |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7491749/ https://ncbi.nlm.nih.gov/pubmed/32939510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xinn.2020.100035 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|